AAOS IDEA Grant Program Opens: Call for Proposals that Fuel the Future of Orthopaedics

Grant program inspires diversity, equity and access for educational, community and outreach initiatives. Application deadline is June 17, 2024

AAOS IDEA Grant Program

The American Academy of Orthopaedic Surgeons (AAOS) announced a call for proposals for the AAOS IDEA Grant Program ®, a multi-year initiative to inspire diversity, equity and access across the field of orthopaedics. Now in its third year, the program will award $300,000 in 2025 to help address decades of inertia surrounding persistent disparities across orthopaedics and, in turn, better serve patients nationwide.

“The programs selected for an AAOS IDEA Grant will help to cultivate meaningful and measurable opportunities across orthopaedics, acting as a springboard for change within our profession,” said AAOS Diversity Advisory Board Chair Holly Tyler-Paris Pilson, MD, FAAOS, FAOA. “This is not about checking a box; this call for proposals opens a door for funding directly to the local and regional orthopaedic programs and organizations who are training the current and next generation.”

The AAOS IDEA Grant Program tracks encompass a wide net to better fund and support a diverse pipeline of individuals who pursue orthopaedics as a profession; foster DEI initiatives for community-based or academic orthopaedic surgeons; and expand the availability of AAOS educational and networking opportunities to diverse students and practicing orthopaedic surgeons. Diversity focus areas of the program include gender, race/ethnicity, LGBTQ+, socioeconomic, veteran status and disability. Program funds will be allocated across four tracks, each with a different DEI focus and target recipient. Additional funding from AAOS supporters may be added to extend the reach of the initiative.
Grant proposals will remain open now through June 17, 2024, at 11:59 p.m. CT.

Applicants are encouraged to review the evaluation criteria and general application terms at aaos.org/IDEA. Grant recipients will be responsible for providing an outcomes report to AAOS to measure impact at the end of the funding period. To read about the 2023 and 2024 IDEA Grant Program recipients, click here or email media@aaos.org.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.